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Objective: To investigate the temporal relationship between
onset of inflammation (as measured by secretory phospho-
lipase A2 (sPLA2) and C reactive protein (CRP)) and the
presence of autoantibodies (IgM rheumatoid factor (IgM RF)
and antibodies against citrullinated peptides (anti-CCP)) in
the preclinical phase of rheumatoid arthritis (RA).
Methods: For 79 patients with RA who had been blood
donors before the onset of disease, a median of 13 serum
samples per patient was available. sPLA2 was measured in
patient and matched control samples and related to previous
CRP, IgM RF, and anti-CCP measurements. The temporal
relationship between the increased markers of inflammation
and autoantibodies was analysed with time lag analysis.
Results: IgM RF and anti-CCP concentrations were signifi-
cantly associated (p,0.001) with concentrations of sPLA2,
CRP, and the combination of sPLA2 and CRP at the same time
point. However, we found no stronger association between
the two autoantibody tests and the three inflammation
measures 1, 2, and 3 years before or after a time point
than for measurements at the same time, in the whole group
or in subgroups of IgM RF and anti-CCP positive patients.
Conclusion: Both the acute phase response and autoanti-
body formation often develop years before the first symptoms
of RA occur, and these phenomena are probably closely
connected in time.
T
he preclinical phase of rheumatoid arthritis (RA) is
characterised by the presence of specific autoantibodies,
such as IgM rheumatoid factor (IgM RF)1–3 and
antibodies against citrullinated peptides (anti-CCP).2 3 One
half of blood donors who later developed RA were found to
be positive for IgM RF and/or anti-CCP at least once before
the onset of RA.3 C reactive protein (CRP) levels, as a marker
of the acute phase response, increase over time in patients
with preclinical RA, with the highest values at the start of the
symptoms. However, it remains unclear whether increased
inflammation, measured by CRP, occurs before, after or
simultaneously with the development of antibodies (IgM RF
and/or anti-CCP) in the preclinical phase of RA.4
This issue is relevant to an understanding of the
pathogenesis of RA: appearance of autoantibodies before a
rise in inflammation markers might suggest an antibody
driven inflammatory response. Conversely, detection of
inflammation before the increase in autoantibodies would
provide evidence that antibody formation only occurs after a
detectable level of inflammation has been reached. In
addition, evidence for a temporary concentration peak of a
marker of inflammation before autoantibody formation
would lend support to the possibility of an infectious process
preceding the development of RA.
Therefore, in the present study secretory phospholipase A2
(sPLA2)—another sensitive marker of the acute phase
response—was measured to investigate the temporal rela-
tionship between the onset of inflammation and the presence
of autoantibodies in the preclinical phase of RA. In addition,
this relationship was also tested using CRP and the
combination of sPLA2 and CRP.
PATIENTS AND METHODS
Study subjects
Since 1984, the Sanquin Blood Bank North West Region in
Amsterdam, The Netherlands, has stored serum from
donated blood at 230 C˚. We identified 79 patients with RA
registered at the Jan van Breemen Institute who donated
blood, in general 2–4 times a year, before the onset of the
symptoms, as described previously.3 For each RA sample, one
control sample was selected, matched for sex, age, and time
of blood donation. sPLA2 was measured with an in-house
enzyme linked immunosorbent assay (ELISA).5 CRP, IgM RF,
and anti-CCP had been determined previously.3 4 The study
was approved by the local Institutional Review Board (ethics
committee: Slotervaart Hospital, Jan van Breemen Institute
and BovenIJ Hospital, Amsterdam, The Netherlands).
Statistical analysis
In a first analysis, the progression of the sPLA2 concentration
over time in the patient and control groups, corrected for age,
sex, and CRP, was estimated with random coefficient
analysis. This longitudinal regression technique was used
because each patient had a different number of measure-
ments at different points in time.
In a second analysis, all patient samples were used to study
the temporal relationship between the increased markers of
inflammation and autoantibodies in preclinical RA with time
lag analyses.6 Concentrations of IgM RF and anti-CCP, on the
one hand, were associated with concentrations of (a) sPLA2;
(b) CRP; and (c) the combination of sPLA2 and CRP (Z score
ln_sPLA2 + Z score ln_CRP), on the other hand, at the same
time point as well as at 1, 2, and 3 years before, and 1, 2, and
3 years after that time. By comparing the magnitude of the
different regression coefficients, one can determine if a time
lag is present. The regression coefficients were calculated by
random coefficient analysis and corrected for age and sex.
Finally, the same time lag analyses were repeated in two
subgroups: (a) the relationship between the increase of IgM
RF and the inflammation markers over time was studied in
Abbreviations: anti-CCP, antibodies against citrullinated peptides;
CRP, C reactive protein; RA, rheumatoid arthritis; RF, rheumatoid factor,
sPLA2, secretory phospholipase A2
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all samples of the patients who were positive for IgM RF at
least once before the onset of the symptoms; and (b) the
relation between anti-CCP and the inflammation markers
was analysed in all serum samples of the patients who were
positive for anti-CCP at least once before the start of the
symptoms.
In all analyses, the natural logs of sPLA2, CRP, IgM RF, and
anti-CCP were used, because of the non-normal distribution
of these variables. Random coefficient analyses were per-
formed with MLwiN (Multilevel Models Project; Institute of
Education, University of London, London, UK), a statistical
program for multilevel analyses.
RESULTS
Seventy nine patients (50 (62%) female; mean age at onset of
symptoms 51 years) who had been blood donors before the
onset of RA were identified. A median of 13 serum samples
per patient (range 1–51) was available; the median time
between the first donation and the onset of the symptoms
was 7.5 years (range 0.1–14.5). In total, 1078 patient sera and
1071 matched control serum samples were tested.
Figure 1 shows the sPLA2 levels of the patients and
controls before the onset of symptoms, corrected for age, sex,
and CRP. The mean sPLA2 level of the patient group
increased significantly over time (p = 0.005) with the highest
values at the onset of the symptoms, whereas the mean
sPLA2 level of the controls remained stable (p = 0.50).
Table 1 shows the results of the time lag analyses in the
group of patients with RA. The concentrations of IgM RF and
anti-CCP were significantly associated (p,0.001) with the
concentrations of sPLA2, CRP, and the combination of sPLA2
and CRP at the same point in time. In the group as a whole,
the association between the two autoantibody tests and the
three inflammation parameters as measured 1, 2, and 3 years
before as well as 1, 2, and 3 years after a point in time was no
stronger than the association based on measurements at that
same point in time.
Also, in the subgroups of IgM RF positive and the anti-CCP
positive patients there was no stronger association between
the antibody tests and the inflammatory measures 1, 2, and
3 years before and after a point in time in comparison with
the association based on measurements at that same time
(data not shown).
DISCUSSION
Serum levels of sPLA2 were increased in the preclinical phase of
patients with RA in comparison with levels of healthy controls,
in a manner similar to CRP, as published previously.4 Both
measures of inflammation were used to study the temporal
relationship between the increased markers of inflammation
and autoantibodies in preclinical RA. The sophisticated
technique of time lag analysis, did not detect a stronger
association between the antibody tests and the inflammatory
measures up to 3 years before or after a point in time in
comparison with measurements at the same time.
In a previous study we concluded that it remained unclear
whether increased inflammation, measured by CRP, occurs
before, after or simultaneously with the development of
autoantibodies in preclinical RA.4 sPLA2 is also increased in
preclinical RA, but the patterns over time of sPLA2 and CRP
differ between individual patients. Therefore, both measures
of inflammation were analysed separately and combined in a
new time lag analysis in an attempt to unravel the sequence
of increased inflammation and raised autoantibody concen-
trations in the preclinical phase of RA. Because again we did
not find a time lag, it is unlikely that a time lag can be found
by adding other inflammatory measures to the analysis, and
the possibility of a simultaneous occurrence of these
phenomena becomes more likely.
A possible explanation for missing an actually existing
time lag might be that the available blood samples, although
numerous, were taken too far apart in time to be able to
detect a short time lag. A possibly temporary sPLA2 or CRP
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Figure 1 Secretory phospholipase A2 (sPLA2) levels before the onset of
symptoms in the preclinical phase of patients with RA and in controls.
Table 1 Association between autoantibodies and measures of inflammation (CRP, sPLA2, and the combination of CRP and
sPLA2) at different points in time
B (95% CI)
CRP sPLA2 CRP + sPLA2
IgM RF
Inflammation 3 years earlier 0.06 (20.01 to 0.12) 0.07 (0.04 to 0.10) 0.18 (0.07 to 0.29)
Inflammation 2 years earlier 0.07 (0.01 to 0.13) 0.05 (0.02 to 0.08) 0.16 (0.06 to 0.25)
Inflammation 1 year earlier 0.12 (0.06 to 0.18) 0.05 (0.01 to 0.08) 0.19 (0.10 to 0.29)
Inflammation at same point in time 0.09 (0.04 to 0.13) 0.07 (0.04 to 0.09) 0.20 (0.13 to 0.27)
Inflammation 1 year later 0.06 (0.00 to 0.12) 0.04 (0.02 to 0.07) 0.15 (0.06 to 0.24)
Inflammation 2 years later 0.11 (0.05 to 0.16) 0.02 (20.01 to 0.04) 0.14 (0.05 to 0.23)
Inflammation 3 years later 0.05 (20.01 to 0.12) 0.02 (20.01 to 0.05) 0.09 (20.01 to 0.20)
Anti-CCP
Inflammation 3 years earlier 0.05 (0.00 to 0.10) 20.02 (20.05 to 0.01) 0.00 (20.09 to 0.09)
Inflammation 2 years earlier 0.03 (20.03 to 0.08) 20.01 (20.03 to 0.02) 0.01 (20.07 to 0.09)
Inflammation 1 year earlier 0.08 (0.03 to 0.13) 0.00 (20.03 to 0.03) 0.08 (20.01 to 0.16)
Inflammation at same point in time 0.05 (0.02 to 0.09) 0.05 (0.02 to 0.07) 0.13 (0.07 to 0.19)
Inflammation 1 year later 0.00 (20.05 to 0.05) 0.01 (20.02 to 0.03) 0.01 (20.07 to 0.04)
Inflammation 2 years later 0.08 (0.03 to 0.14) 0.02 (0.00 to 0.05) 0.13 (0.04 to 0.21)
Inflammation 3 years later 0.06 (20.01 to 0.13) 0.01 (20.02 to 0.05) 0.09 (20.01 to 0.19)
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peak indicative of an infectious process involved in causing
the RA might also have been missed because the samples
were obtained too far apart. The opposite conclusion, that
because there is no evidence for a time lag, the phenomena of
inflammation and autoantibody formation must be inti-
mately coupled, is likely to be true but cannot be established
beyond doubt on the basis of the present data. Support for
the possibility of simultaneous development comes from the
observed link between local antibody production and level of
inflammation in the rheumatoid synovium.7 In the somewhat
different situation of B cell depletion in established RA, the
relapse of active arthritis after recovery from this depletion
coincides with increasing CRP levels, which are preceded by a
rise in autoantibody levels.8
In conclusion, both the acute phase response and autoanti-
body formation often develop years before the first symptoms
of RA occur, and these phenomena are probably closely
connected in time.
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